Showing results (61-70 of 133) with videos related to
Sort By:
Pageof 14
Oncology Reports|February 8, 2014
Alteration of gene expression and DNA methylation in drug-resistant gastric cancerOsamu Maeda, Takafumi Ando, Naoki Ohmiya, et al.Cancer Medicine|February 13, 2024
Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancerOsamu Maeda, Satoshi Furune, Mitsuro Kanda, et al.Asia-Pacific Journal of Clinical Oncology|July 5, 2023
A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomyYao Liang, Osamu Maeda, Kazushi Miyata, et al.Molecular and Clinical Oncology|October 4, 2014
Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancerOsamu Maeda, Takafumi Ando, Kazuhiro Ishiguro, et al.International Journal of Colorectal Disease|July 18, 2020
What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?Atsushi Ogura, Kay Uehara, Toshisada Aiba, et al.Cancer Genetics and Cytogenetics|October 16, 2002
Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factorYoshitaka Sekido, Mitsuo Sato, Noriyasu Usami, et al.International Cancer Conference Journal|February 4, 2022
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancerYuko Takano, Satoshi Furune, Yuki Miyai, et al.World Journal of Gastroenterology|March 2, 2017
Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility studyOsamu Maeda, Ayumu Matsuoka, Ryoji Miyahara, et al.Oncogene|July 12, 2005
Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancerTakayuki Fukui, Masashi Kondo, Genshi Ito, et al.Journal of Hepato-Biliary-Pancreatic Sciences|June 29, 2026
Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01)Junpei Yamaguchi, Hideki Takami, Yukihiro Yokoyama, et al.Pageof 14